Alnylam Pharmaceuticals (ALNY)

[helios]

i wonder if i've any opportunity with ALNY?


As summaried from the JP Morgan Slides:-

Q3'09 Financial Results
- Cash ~$453M
- GAAP Operating Expenses ~ $33.9M
- GAAP Revenues ~$24.2M (generated from Takeda, Roche, Novartis, Cubist, Biogen Idex, NH, InterfeRx/ Reagent licenses
- Shares outstanding ~ 41.8M

As per Q3'09, ALNY claims to have zero debt?

TOL: ALNY seems to be doing the publicity stunt as well in the Cowen and Company’s 30th Annual Health Care Conference on Tuesday, March 9, 2010, at 4:30 p.m. ET at the Boston Marriott Copley Place ...

Alnylam Key Goals for the next 12 - 18 months

1. Advance clinical pipeline to human PoC
- ALN-RSV01: Initiate Phase IIb, 1Q 2010
- ALN-VSP: Prelim data 2H 2010
- ALN-TTR01: Initiate Phase I, 1H 2010 (and advance ALN-TTR02 with 2nd gen LNP program)
- ALN-PCS: Initiate Phase I by 2011
- Advance additional pre-clinical programs (ALN-RSV02, ALN-HTT)

2. Continued scientic and delivery leadership
- Publish 15+ major scientific publications
- Continue major progress in delivery

3. Continued leadership on business execution
- Continue IP dominance with 30+ new patent grants
- Form new partnerships

4. Maintain solid financial performance
- Target > $325M in end 2010? And this will exclude potential Norvatis adoption license?

[helios]

Some prices i've on chart:-

- Upper band at 20 - 23
- Lower band at 16.6
- 14 days MA at 17.7 (current price; same as 25 days MA)

[winston]

not vested

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference.

The company's clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR);

ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis;

Fitusiran, an investigational RNAi therapeutic that is in Phase I clinical trial for the treatment of hemophilia and rare bleeding disorders;

ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-AS1 for the treatment of hepatic porphyrias.

Source: Today's Big Stock

http://todaysbigstock.com/2016/08/02/al ... sdaq-alny/